Avalo Therapeutics, Inc. (AVTX) stock rallied over 0.99% intraday to trade at $0.50 a share on NASDAQ. The stock opened with a loss of -3.29% at $0.486 and touched an intraday high of $0.548, rising 1.01% against the last close of $0.495. The stock went to a low of $0.486 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue5.4 Million
5Y Sales Change36.20%
Fiscal Year Ends2021-12-30
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Its product pipeline includes AVTX-002, an Anti-LIGHT mAb targeting immune-inflammatory diseases, including acute respiratory distress syndrome and moderate-to-severe inflammatory bowel disease; and AVTX-007, an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases, including multiple myeloma and Still's disease. The company also engages in developing AVTX-006, a dual mTORc1/c2 inhibitor targeting lymphatic malformations; and AVTX 800 programs (AVTX-801, AVTX-802, and AVTX-803), which are therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) stock price is $0.5 as of the last check on Thursday, June 30. During the trading session, AVTX stock reached the peak price of $0.548 while $0.486 was the lowest point it dropped to.
The NASDAQ listed AVTX is part of Biotechnology industry that operates in the broader Health Care sector. Avalo Therapeutics, Inc. , a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
Dr. H. Jeffery Wilkins M.D.
Chief Medical Officer
Mr. Stephen Smolinski
Chief Commercial Officer
Dr. Garry A. Neil M.D.
Pres & CEO
Dr. Solomon H. Snyder M.D.
Founder and Chairman of Scientific Advisory Board
AVTX stock traded closed the last session at $0.5, which is $0.00 or 0.99% lower than its previous close of $0.495. AVTX's current trading price is 147.65% lower than its 52-week high of $3.43 where as its distance from 52-week low of 0.20% is -85.42%.
Number of AVTX employees currently stands at -. AVTX operates from 540 Gaither Road, Suite 400, Rockville, MD 20850, United States.
Official Webiste of $AVTX is: https://www.avalotx.com
AVTX stock volume for the day was 70,914 shares while in the previous session number of AVTX shares traded was 70,914 . The average number of AVTX shares traded daily for last 3 months was 582.18 Thousands.
The percentage change in AVTX stock occurred in the recent session was 0.99% while the dollar amount for the price change in AVTX stock was $0.00.
In the recent session, the day high for AVTX stock was $0.548 while the low for AVTX stock touched on the day was $0.486.
The market value of AVTX currently stands at 59.88 Million with its latest stock price at $0.5 and 112.79 Million of its shares outstanding.